A detailed history of Thrivent Financial For Lutherans transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 110,389 shares of IRWD stock, worth $464,737. This represents 0.0% of its overall portfolio holdings.

Number of Shares
110,389
Previous 116,123 4.94%
Holding current value
$464,737
Previous $757,000 39.89%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$3.93 - $7.04 $22,534 - $40,367
-5,734 Reduced 4.94%
110,389 $455,000
Q2 2024

Aug 13, 2024

SELL
$5.58 - $8.61 $17,125 - $26,424
-3,069 Reduced 2.57%
116,123 $757,000
Q1 2024

May 14, 2024

SELL
$8.32 - $15.45 $26,923 - $49,996
-3,236 Reduced 2.64%
119,192 $1.04 Million
Q4 2023

Feb 14, 2024

SELL
$8.79 - $11.51 $27,943 - $36,590
-3,179 Reduced 2.53%
122,428 $1.4 Million
Q3 2023

Nov 14, 2023

SELL
$8.25 - $11.35 $30,376 - $41,790
-3,682 Reduced 2.85%
125,607 $1.21 Million
Q2 2023

Aug 14, 2023

SELL
$10.1 - $11.6 $29,946 - $34,394
-2,965 Reduced 2.24%
129,289 $1.38 Million
Q1 2023

May 17, 2023

SELL
$10.37 - $12.56 $48,075 - $58,228
-4,636 Reduced 3.39%
132,254 $1.39 Million
Q4 2022

Feb 08, 2023

SELL
$9.9 - $12.43 $9,068 - $11,385
-916 Reduced 0.66%
136,890 $1.7 Million
Q3 2022

Nov 14, 2022

SELL
$10.14 - $12.38 $135,206 - $165,074
-13,334 Reduced 8.82%
137,806 $1.43 Million
Q2 2022

Aug 16, 2022

BUY
$11.05 - $12.72 $1.67 Million - $1.92 Million
151,140 New
151,140 $1.74 Million
Q1 2018

May 08, 2018

SELL
$11.13 - $13.63 $1.91 Million - $2.34 Million
-171,386 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$12.07 - $14.87 $2.07 Million - $2.55 Million
171,386
171,386 $2.7 Million

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $645M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.